Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling

Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H et al. (2005). Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65: 226–235.

Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G . (1996). All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271: 5251–5257.

Dikic I, Giordano S . (2003). Negative receptor signalling. Curr Opin Cell Biol 15: 128–135.

Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. (2005). ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102: 3788–3793.

Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS et al. (2005). Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proc Natl Acad Sci USA 102: 1915–1920.

Graus Porta D, Beerli RR, Daly JM, Hynes NE . (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647–1655.

Hynes NE, Horsch K, Olayioye MA, Badache A . (2001). The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer 8: 151–159.

Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus Porta D, Ratzkin BJ et al. (1996). ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15: 254–264.

Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New Engl J Med 352: 786–792.

Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG et al. (1989). Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58: 287–292.

Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y . (1996). Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 12: 1117–1125.

Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I et al. (1999). Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4: 1029–1040.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.

Marmor MD, Yarden Y . (2004). Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23: 2057–2070.

Muthuswamy SK, Gilman M, Brugge JS . (1999). Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 19: 6845–6857.

Ouyang X, Gulliford T, Zhang H, Smith G, Huang G, Epstein RJ . (2001). Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer. Mol Cell Biochem 218: 47–54.

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500.

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. (2004). EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306–13311.

Pao W, Miller VA, Politi KA, Rieli GJ, Somwar R, Zakowski MF et al. (2005). Acquired resistance of lung adenocarcinomas to Gefitinib or Erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine 2: e73.

Polo S, Sigismund S, Faretta M, Guidi M, Capua MR, Bossi G et al. (2002). A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature 416: 451–455.

Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P et al. (2005). Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA 102: 2760–2765.

Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A et al. (1994). Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269: 14661–14665.

Sordella R, Bell DW, Haber DA, Settleman J . (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163–1167.

Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA . (2004). Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 64: 7241–7244.

Waterman H, Alroy I, Strano S, Seger R, Yarden Y . (1999). The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J 18: 3348–3358.

Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A et al. (2002). A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J 21: 303–313.

Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG . (1990). Ligand-induced transformation by a non-internalizing epidermal growth factor receptor. Science 247: 962–964.

Wiley HS, Burke PM . (2001). Regulation of receptor tyrosine kinase signaling by endocytic trafficking. Traffic 2: 12–18.

Worthylake R, Opresko LK, Wiley HS . (1999). ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274: 8865–8874.

Yang S, Qu S, Perez-Tores M, Sawai A, Rosen N, Solit DB et al. (2006). Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res 66: 6990–6997.

Yarden Y, Sliwkowski MX . (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137.